Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Clin Cardiol. 2011 Apr;34(4):254-60. doi: 10.1002/clc.20861.
Although recent federal mandate provides incentives for physicians to use electronic prescribing (e-prescribing), clinical end points to support its use are lacking.
E-prescribing should improve low-density lipoprotein (LDL) goal attainment.
In this retrospective cohort study, we queried the electronic medical records (Allscripts Electronic Health Record [EHR]) of a multispecialty outpatient academic medical practice to identify patient encounters during which consecutive lipid panels were drawn in 2007 (n = 2218). The EHR did not include a clinical decision tool for guideline adherence but did include formulary decision support (FDS), which informs physicians about drug costs specific to each patient. Logistic regression was used to examine whether the odds of reaching LDL goal were influenced by e-prescribing and adjusted for characteristics known to affect prescribing patterns and goal attainment.
Of 796 patients not at LDL goal at baseline, 49% (n = 393) were at goal at follow-up. Patients receiving an e-prescription with FDS were 59% more likely to achieve LDL goal than those with a manual prescription (95% confidence interval [CI]: 1.12-2.25). Superior LDL goal attainment may be from lower cost of medications; patients with an e-prescription were significantly more likely to receive a generic statin than patients with a manual prescription (38% vs 22.9%; P = 0.0004), and for each $10 increase in prescription price, the likelihood of being at goal decreased by 5% (odds ratio = 0.95; 95% CI: 0.93-0.98).
Our study is the first to demonstrate that e-prescribing with FDS is associated with improved LDL goal attainment. Therefore, e-prescribing can deliver tangible clinical gains to patients, likely from improved adherence to more affordable treatment.
尽管最近的联邦指令为医生使用电子处方(e-prescribing)提供了激励措施,但缺乏支持其使用的临床终点。
电子处方应该提高低密度脂蛋白(LDL)目标的达标率。
在这项回顾性队列研究中,我们查询了一家多专科门诊学术医疗实践的电子病历(Allscripts 电子健康记录[EHR]),以确定在 2007 年连续抽取血脂谱的患者就诊情况(n=2218)。EHR 中没有用于遵循指南的临床决策工具,但包含了处方决策支持(FDS),它会向医生提供每个患者具体药物成本的信息。使用逻辑回归来检查电子处方是否会影响 LDL 目标的达标率,并根据已知会影响处方模式和目标达标率的特征进行调整。
在基线时未达到 LDL 目标的 796 名患者中,有 49%(n=393)在随访时达到了目标。接受 FDS 电子处方的患者达到 LDL 目标的可能性比接受手动处方的患者高 59%(95%置信区间[CI]:1.12-2.25)。LDL 目标达标率的提高可能是由于药物成本较低所致;接受电子处方的患者比接受手动处方的患者更有可能使用通用他汀类药物(38%对 22.9%;P=0.0004),并且处方价格每增加 10 美元,达标率就会降低 5%(比值比=0.95;95%CI:0.93-0.98)。
我们的研究首次表明,FDS 辅助的电子处方与 LDL 目标达标率的提高相关。因此,电子处方可以为患者带来切实的临床收益,可能是因为提高了对更经济实惠的治疗方法的依从性。